Futures rise as focus turns to Powell speech



(For a Reuters live blog on U.S., UK and European stock markets, click

or type LIVE/ in a news window.)

*

Tesla up as sales in China nearly double in November

*

Biogen rises after "clean" Alzheimer's drug data

*

Fed Chair Powell's speech at 1330 EST (1830 GMT)

*

Futures up: Nasdaq 0.38%, Dow 0.07%, S&P 0.20%

By Shreyashi Sanyal

Nov 30 (Reuters) - U.S. stock index futures edged higher on Wednesday, with those of the Nasdaq rising the most on gains in Tesla shares, while investors treaded cautiously ahead of comments from Federal Reserve Chair Jerome Powell later in day.

Powell's speech will be closely watched for signs of a slowdown in the pace of interest rate hikes by the central bank as well as to assess the general health of the U.S. economy.

"Fed Chair Powell is speaking, but past comments have done little other than chant 'hike, hike, hike'," said Paul Donovan, chief economist, UBS Global Wealth Management.

"Powell has yet to explain the mechanism by which hiking rates is supposed to reduce inflation (which matters to analyzing when rates might peak) ... today's speech should signal a slowing of rate hikes."

Hopes that the Fed will now hike rates in smaller increments and recent data pointing to a mild cooling in prices have positioned the benchmark S&P 500 index .SPX for its second straight month of gains.

The Dow Jones Industrial Average .DJI has gained nearly 18% in the last two months, while the Nasdaq index .IXIC has added about 4%.

Traders see the Fed increasing rates by 50 basis points in December, with the rates peaking in June 2023.

Electric-vehicle maker Tesla Inc TSLA.O shares rose 1.4% in premarket trading as its sales in November were boosted by price cuts and incentives offered on its Model 3 and Model Y, according to data from China Merchants Bank International (CMBI).

The company led gains among other growth stocks, including Apple Inc AAPL.O , Microsoft Corp MSFT.O and Amazon.com Inc AMZN.O , all of which rose between 0.5% and 0.6%.

Boeing Co BA.N shares gained 1.4% after U.S. Senate Commerce Committee Chair Maria Cantwell drafted a proposal granting exceptions for its two 737 MAX variants if they include safety enhancements.

At 6:47 a.m. ET, Dow e-minis 1YMcv1 were up 24 points, or 0.07%, S&P 500 e-minis EScv1 were up 8 points, or 0.2%, and Nasdaq 100 e-minis NQcv1 were up 44.25 points, or 0.38%.

Biogen Inc BIIB.O rose 4.0% after its experimental Alzheimer's drug made along with Japanese co Eisai Co Ltd 4523.T slowed cognitive decline in a closely watched trial.

On the data front, the U.S. Commerce Department will release its second estimate of third-quarter gross domestic product. The report is expected to show the economy grew at a 2.7% annualized rate, slightly above the department's previous projection of 2.6%.

An ADP National Employment report is set to show that private employment increased by 200,000 jobs in November, compared with 239,000 jobs added in the previous month.
Reporting by Shreyashi Sanyal & Devik Jain; Additional reporting by Shubham Batra; Editing by Anil D'Silva

Disclaimer: The XM Group entities provide execution-only service and access to our Online Trading Facility, permitting a person to view and/or use the content available on or via the website, is not intended to change or expand on this, nor does it change or expand on this. Such access and use are always subject to: (i) Terms and Conditions; (ii) Risk Warnings; and (iii) Full Disclaimer. Such content is therefore provided as no more than general information. Particularly, please be aware that the contents of our Online Trading Facility are neither a solicitation, nor an offer to enter any transactions on the financial markets. Trading on any financial market involves a significant level of risk to your capital.

All material published on our Online Trading Facility is intended for educational/informational purposes only, and does not contain – nor should it be considered as containing – financial, investment tax or trading advice and recommendations; or a record of our trading prices; or an offer of, or solicitation for, a transaction in any financial instruments; or unsolicited financial promotions to you.

Any third-party content, as well as content prepared by XM, such as: opinions, news, research, analyses, prices and other information or links to third-party sites contained on this website are provided on an “as-is” basis, as general market commentary, and do not constitute investment advice. To the extent that any content is construed as investment research, you must note and accept that the content was not intended to and has not been prepared in accordance with legal requirements designed to promote the independence of investment research and as such, it would be considered as marketing communication under the relevant laws and regulations. Please ensure that you have read and understood our Notification on Non-Independent Investment. Research and Risk Warning concerning the foregoing information, which can be accessed here.

We are using cookies to give you the best experience on our website. Read more or change your cookie settings.

Risk Warning: Your capital is at risk. Leveraged products may not be suitable for everyone. Please consider our Risk Disclosure.